14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Monday, 6th May 2024 CMRA stock ended at $0.0212. This is 29.33% less than the trading day before Friday, 3rd May 2024. During the day the stock fluctuated 41.51% from a day low at $0.0212 to a day high of $0.0300.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Comera Life Sciences Holdings, Inc. prices

Date Open High Low Close Volume
May 06, 2024 $0.0300 $0.0300 $0.0212 $0.0212 2
May 03, 2024 $0.0300 $0.0300 $0.0300 $0.0300 0
May 02, 2024 $0.0300 $0.0300 $0.0300 $0.0300 41 072
May 01, 2024 $0.0361 $0.0381 $0.0361 $0.0361 58 916
Apr 30, 2024 $0.0361 $0.0400 $0.0361 $0.0400 2 250
Apr 29, 2024 $0.0361 $0.0361 $0.0361 $0.0361 0
Apr 26, 2024 $0.0361 $0.0361 $0.0361 $0.0361 267
Apr 25, 2024 $0.0215 $0.0400 $0.0215 $0.0361 134 565
Apr 24, 2024 $0.0410 $0.0410 $0.0410 $0.0410 0
Apr 23, 2024 $0.0410 $0.0410 $0.0410 $0.0410 3 046
Apr 22, 2024 $0.0410 $0.0410 $0.0410 $0.0410 100
Apr 19, 2024 $0.0410 $0.0410 $0.0410 $0.0410 2 416
Apr 18, 2024 $0.0410 $0.0410 $0.0410 $0.0410 170
Apr 17, 2024 $0.0500 $0.0500 $0.0410 $0.0410 2 000
Apr 16, 2024 $0.0595 $0.0595 $0.0595 $0.0595 1 500
Apr 15, 2024 $0.0340 $0.0595 $0.0340 $0.0595 79 370
Apr 12, 2024 $0.0375 $0.0380 $0.0370 $0.0380 12 061
Apr 11, 2024 $0.0370 $0.0370 $0.0370 $0.0370 5 103
Apr 10, 2024 $0.0400 $0.0400 $0.0370 $0.0400 40 113
Apr 09, 2024 $0.0374 $0.0407 $0.0340 $0.0400 10 994
Apr 08, 2024 $0.0407 $0.0407 $0.0340 $0.0340 4 675
Apr 05, 2024 $0.0374 $0.0407 $0.0374 $0.0407 3 202
Apr 04, 2024 $0.0363 $0.0363 $0.0340 $0.0350 4 193
Apr 03, 2024 $0.0350 $0.0350 $0.0350 $0.0350 100
Apr 02, 2024 $0.0340 $0.0340 $0.0340 $0.0340 11 000
Click to get the best stock tips daily for free!

About Comera Life Sciences Holdings, Inc.

Comera Life Sciences Holdings. Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis dis... CMRA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT